Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 17, 2024 - Issue
Submit an article Journal homepage
168
Views
0
CrossRef citations to date
0
Altmetric
SHORT REPORT

Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma

Mark Gurnell1 Department of Medicine, Wellcome–MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK;2 NIHR Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, Cambridge, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5745-6832View further author information
ORCID Icon,
Amr Radwan3 Global Medical Affairs, Regeneron Pharmaceuticals Inc., Uxbridge, UKORCID Iconhttps://orcid.org/0000-0003-1658-5229View further author information
ORCID Icon,
Claus Bachert4 Department of Otorhinolaryngology – Head and Neck Surgery, University Hospital of Münster, Münster, Germany;5 International Airway Research Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China;6 Division of ENT Diseases, CLINTEC, Karolinska Hospital, Stockholm University, Stockholm, SwedenView further author information
,
Njira Lugogo7 Division of Pulmonary & Critical Care Medicine, University of Michigan, Ann Arbor, MI, USAView further author information
,
Seong H Cho8 Division of Allergy-Immunology, Morsani College of Medicine, University of South Florida, Tampa, FL, USAORCID Iconhttps://orcid.org/0000-0003-0933-953XView further author information
ORCID Icon,
Scott Nash9 Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USAORCID Iconhttps://orcid.org/0000-0001-9208-5280View further author information
ORCID Icon,
Haixin Zhang9 Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USAView further author information
,
Asif H Khan10 Global Medical Affairs, Sanofi, Chilly-Mazarin, FranceORCID Iconhttps://orcid.org/0000-0001-9158-0116View further author information
ORCID Icon,
Juby A Jacob-Nara11 Global Medical Affairs, Sanofi, Bridgewater, NJ, USAORCID Iconhttps://orcid.org/0000-0002-5372-8762View further author information
ORCID Icon,
Paul J Rowe11 Global Medical Affairs, Sanofi, Bridgewater, NJ, USAView further author information
&
Yamo Deniz9 Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USAView further author information
 show all
Pages 1-8 | Received 19 May 2023, Accepted 11 Dec 2023, Published online: 16 Jan 2024

References

  • Ragab A, Clement P, Vincken W. Objective assessment of lower airway involvement in chronic rhinosinusitis. Am J Rhinol. 2004;18(1):15–21. doi:10.1177/194589240401800105
  • Khan A, Huynh TMT, Vandeplas G, et al. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. Rhinology. 2019;57(5):343–351. doi:10.4193/Rhin19.158
  • Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319. doi:10.1111/all.13875
  • Meier EC, Schmid-Grendelmeier P, Steiner UC, Soyka MB. Real-life experience of monoclonal antibody treatments in chronic rhinosinusitis with nasal polyposis. Int Arch Allergy Immunol. 2021;182(8):736–743. doi:10.1159/000514262
  • Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi:10.1080/1744666x.2017.1298443
  • Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi:10.1111/all.14151
  • Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology. 2021;59(3):301–311. doi:10.4193/Rhin20.415
  • Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi:10.1016/s0140-6736(19)31881-1
  • Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018
  • Klain A, Indolfi C, Dinardo G, et al. United airway disease. Acta Biomed. 2021;92(S7):e2021526. doi:10.23750/abm.v92iS7.12399
  • Mullol J, Maldonado M, Castillo JA, et al. Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. J Allergy Clin Immunol Pract. 2022;10(9):2438–2447.e2439. doi:10.1016/j.jaip.2022.04.039
  • Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. doi:10.1016/j.jaip.2020.09.063
  • Busse WW, Pavord ID, Siddiqui S, et al. Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma irrespective of baseline asthma characteristics. J Asthma Allergy. 2023;16:411–419. doi:10.2147/jaa.S391896
  • Rabe KF, Pavord ID, Busse WW, et al. Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status. Allergy. 2023;78(8):2148–2156. doi:10.1111/all.15747
  • Bachert C, Khan A, Lee S, et al. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52. Int Forum Allergy Rhinol. 2023 1–10. doi:10.1002/alr.23249

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.